GBM Market

Over the past decades, there has been an eruption in understanding treatment strategies of gliomas with the development of clinical immunotherapy, providing exceptional success in employing checkpoint inhibitors and cancer vaccines as treatment options that have given significant momentum to the growth of the GBM m...

The present Glioblastoma multiforme (GBM) market has several unmet needs. Poor prognosis, 10-15 months median survival rate, no curative treatment to the patients, limited treatment options, drug resistance, incapability of therapies to cross BBB (blood-brain-barrier), intratumor heterogeneity, and a high mortality...